AB Cube Germany, a leading provider of eClinical software and the developer of the Marvin EDC platform today announced the upcoming launch of Marvin Study Designer, an AI-assisted application that enables clinical data managers to generate complete, standards-compliant study definitions in minutes from a simple study description or an uploaded protocol. Designed as a companion to the Marvin EDC platform, the solution helps accelerate one of the most time-consuming phases of clinical trial startup while ensuring experts remain fully in control.

Marvin Study Designer generates complete study structures including visits, forms, fields, controlled terminology, and validation rules from plain-language prompts or protocol documents. Every draft is informed by a knowledge base of more than 840 real CDISC ODM study definitions, producing review-ready designs that follow proven clinical data management practices rather than relying on AI-generated assumptions.

In contrast to other cloud-based AI solutions, Marvin Study Designer runs entirely within our own infrastructure. No study protocols, patient data, or other sensitive information are sent to external data processors, making it well suited for organizations with strict security and compliance requirements.

The application is built around a human-in-the-loop approach: AI creates the initial draft, while clinical experts review and approve every element before deployment. A built-in validation engine checks each study against Marvin’s import schema and business rules, helping ensure consistency, quality, and compliance before publication.

Beyond study design, Marvin Study Designer can automatically generate edit checks, synthetic patient data, and test users to support faster study validation and testing before go-live.

"Marvin Study Designer combines the speed of AI with the oversight required for regulated clinical research," said Manuel Neukum, CEO of AB Cube Germany. "It enables clinical teams to reduce manual effort, accelerate study startup, and confidently use AI without compromising data security or quality."

To learn more or request a demonstration, visit www.marvin.now.

 

Über die AB Cube Germany GmbH

Marvin EDC is the flagship product of AB Cube Germany (formerly XClinical), a leading leading European provider of eClinical technologies, delivering innovative software solutions that enable sponsors, CROs, and research organizations to manage clinical trials more efficiently

Marvin, is designed to simplify and accelerate clinical trial management through a modern, unified architecture. The Marvin EDC Suite includes integrated modules such as eCRF, ePRO/eCOA, RTSM, eConsent, Risk-Based Monitoring (RBM), Medical Coding, and Safety reconciliation, providing a seamless environment for clinical data collection and trial oversight. AI-assisted capabilities further streamline study design, validation, and user acceptance testing, helping teams reduce setup time, improve data quality, and accelerate study delivery.

As a brand of AB Cube Germany, Marvin builds on more than two decades of experience in delivering innovative software solutions for clinical research. The platform is designed to support studies of all sizes and complexities while ensuring regulatory compliance, operational efficiency, and an outstanding user experience.

www.marvin.now

Firmenkontakt und Herausgeber der Meldung:

AB Cube Germany GmbH
Rosental 5
80331 München
Telefon: +49 (89) 4522775000
https://marvin.now

Ansprechpartner:
Sabine Birkner
Marketing
Telefon: 0894522775000
E-Mail: sabine.birkner@marvin.now
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel